It was quite a comedown in the 1970s when research into psychedelic medicine was virtually shut down in the West. Many countries were beginning to classify psychedelics as “schedule 1”, making them illegal, on the grounds that they were drugs of “abuse” with no agreed-upon medical use.
The stigma, and many obstacles, remain. For many people – crucially those who hold the purse strings – research into psychedelic drugs has a whiff of disreputability about it. As our exclusive interview with Robin Carhart-Harris of Imperial College London reveals, anyone daring to lead this science has to perform a balancing act, with their reputations always on the line.
Nevertheless, the field is showing the green shoots of a renaissance. Here’s a round up of New Scientist’s coverage on the potential, the people and the politics of psychedelic medicine….
Many creators of psychedelic drugs famously tested their products on themselves first. Alexander Shulgin, considered the world’s foremost “psychonaut”, is among those featured in our gallery of self-experimenters.
Over the years, New Scientist has interviewed many key players in psychedelics research, including: Robin Carhart-Harris; David Nutt of Imperial College London, also a former advisor to the UK government on the misuse of drugs; Amanda Feilding, a drugs policy reformer who founded the Beckley Foundation, which promotes and funds clinical research into the therapeutic possibilities of psychedelics; Rick Doblin of the Multidisciplinary Association for Psychedelic Studies in Santa Cruz, California; and Torsten Passie of Hannover Medical School. From the other side of the fence, we’ve spoken to medicine maker David Nichols, whose work was subverted by manufacturers of recreational drugs; and a maker of legal highs, Dr Z, who argued that mind-altering drugs should be legalised for the improvement of society.
ADD article topics at the end of the article